AVITA MedicalRCEL +0.64%66 EBITDA Margin % is -44.52% as of Mar. 2026. GuruFocus rates RCEL with a GF Score™ of 66/100 and a GF Value™ of $10.78 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, AVITA Medical ranks worse than 78.92% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. AVITA Medical's EBITDA for the
three
months ended in Mar. 2026 was $-8.57 Mil. AVITA Medical's Revenue for the
three
months ended in Mar. 2026 was $19.25 Mil. Therefore, AVITA Medical's EBITDA margin for the quarter that ended in Mar. 2026 was -44.52%.
AVITA Medical (NAS:RCEL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
AVITA Medical EBITDA Margin % Related Terms
AVITA Medical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for AVITA Medical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RCEL vs NNOX, MXCT, SNWV: EBITDA Margin % Comparison
For the Medical Devices subindustry, AVITA Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AVITA Medical EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where AVITA Medical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVITA Medical (RCEL) has a EBITDA Margin % of -44.52% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AVITA Medical and its competitors. According to the industry distribution chart, AVITA Medical ranks #644 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 78.9%.
Is AVITA Medical's EBITDA Margin % too high?
AVITA Medical's current EBITDA Margin % is -44.52%. Based on the distribution chart, AVITA Medical ranks #644 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, AVITA Medical has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AVITA Medical's EBITDA Margin % compare to NNOX and MXCT?
According to the Medical Devices & Instruments industry distribution chart, AVITA Medical ranks #644 out of 816 companies for EBITDA Margin %. This places AVITA Medical in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AVITA Medical and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AVITA Medical's current EBITDA Margin % is -44.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AVITA Medical stock overvalued right now?
Based on GuruFocus' analysis, AVITA Medical (RCEL) is currently considered Possible Value Trap. The stock's GF Value™ is $10.78, compared to a current price of $3.95 — trading 63.4% below its estimated fair value. The current EBITDA Margin % is -44.52%. AVITA Medical's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For AVITA Medical (RCEL), the current EBITDA Margin % is -44.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AVITA Medical (RCEL) Overvalued in 2026?
Based on GuruFocus' analysis, AVITA Medical stock appears to be undervalued.
The current stock price of $3.95 is trading 63.4% below its estimated GF Value™ of $10.78.
GuruFocus considers AVITA Medical to be Possible Value Trap.
Key valuation signals for RCEL:
EBITDA Margin %: -44.52%
GF Value™: $10.78 vs. price of $3.95 (63.4% below fair value)
No single metric tells the full story. See the RCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
66GF Score
Get the complete analysis for RCEL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RCEL has been successfully added to your 
